The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators*

The human estrogen receptor α-isoform (ERα) is a nuclear transcription factor that displays a complex pharmacology. In addition to classical agonists and antagonists, the transcriptional activity of ERα can be regulated by selective estrogen receptor modulators, a new class of drugs whose relative agonist/antagonist activity is determined by cell context. It has been demonstrated that the binding of different ligands to ERα results in the formation of unique ERα-ligand conformations. These conformations have been shown to influence ERα-cofactor binding and, therefore, have a profound impact on ERα pharmacology. In this study, we demonstrate that the nature of the bound ligand also influences the stability of ERα, revealing an additional mechanism by which the pharmacological activity of a compound is determined. Of note we found that although all ERα-ligand complexes can be ubiquitinated and degraded by the 26 S proteasome in vivo, the mechanisms by which they are targeted for proteolysis appear to be different. Specifically, for agonist-activated ERα, an inverse relationship between transcriptional activity and receptor stability was observed. This relationship does not extend to selective estrogen receptor modulators and pure antagonists. Instead, it appears that with these compounds, the determinant of receptor stability is the ligand-induced conformation of ERα. We conclude that the different conformational states adopted by ERα in the presence of different ligands influence transcriptional activity directly by regulating cofactor binding and indirectly by modulating receptor stability.

[1]  D. Ecker,et al.  A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. , 1989, Science.

[2]  V. Jordan,et al.  Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. , 1988, Cancer research.

[3]  Martin Rechsteiner,et al.  Recognition of the polyubiquitin proteolytic signal , 2000, The EMBO journal.

[4]  A. Howell,et al.  Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer , 1995, The Lancet.

[5]  J. Trowsdale,et al.  Dynamics of proteasome distribution in living cells , 1997, The EMBO journal.

[6]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[7]  A. Philips,et al.  Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. , 1993, The Journal of biological chemistry.

[8]  O. Jänne,et al.  Ubc9 Interacts with the Androgen Receptor and Activates Receptor-dependent Transcription* , 1999, The Journal of Biological Chemistry.

[9]  M. Imhof,et al.  Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors , 1996, Molecular and cellular biology.

[10]  J. Davie,et al.  Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor. , 1999, Molecular biology of the cell.

[11]  B. O’Malley,et al.  The 26S Proteasome Is Required for Estrogen Receptor-α and Coactivator Turnover and for Efficient Estrogen Receptor-α Transactivation , 2000 .

[12]  H Grøn,et al.  Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Guenther,et al.  Proteasomal regulation of nuclear receptor corepressor-mediated repression. , 1998, Genes & development.

[14]  B. Katzenellenbogen,et al.  Antiestrogens: Mechanisms and actions in target cells , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[15]  K.,et al.  Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. Schaffner,et al.  Identification of a novel lymphoid specific octamer binding protein (OTF‐2B) by proteolytic clipping bandshift assay (PCBA). , 1988, The EMBO journal.

[17]  D. Moore,et al.  Interaction of thyroid-hormone receptor with a conserved transcriptional mediator , 1995, Nature.

[18]  L. Staszewski,et al.  Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain , 1994, Cell.

[19]  D. Fowlkes,et al.  Peptide antagonists of the human estrogen receptor. , 1999, Science.

[20]  M. Parker,et al.  The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. , 1993, Journal of cell science.

[21]  B. O’Malley,et al.  Proteasome-dependent degradation of the human estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Parker,et al.  Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Schreiber,et al.  A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[25]  R F Standaert,et al.  Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin , 1995, Science.

[26]  M. Stallcup,et al.  Enhancement of Estrogen Receptor Transcriptional Activity by the Coactivator GRIP-1 Highlights the Role of Activation Function 2 in Determining Estrogen Receptor Pharmacology* , 1998, The Journal of Biological Chemistry.

[27]  O. Staub,et al.  Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination , 1997, The EMBO journal.

[28]  V. Chau,et al.  A uniform isopeptide-linked multiubiquitin chain is sufficient to target substrate for degradation in ubiquitin-mediated proteolysis. , 1990, The Journal of biological chemistry.

[29]  D. McDonnell,et al.  Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. , 1996, Molecular endocrinology.

[30]  Jun Ma,et al.  GAL4-VP16 is an unusually potent transcriptional activator , 1988, Nature.

[31]  B. Katzenellenbogen,et al.  Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. , 1984, Endocrinology.

[32]  G. Leclercq,et al.  Implication of proteasome in estrogen receptor degradation , 1999, FEBS letters.

[33]  P. Deininger,et al.  Identification of a New Subclass of Alu DNA Repeats Which Can Function as Estrogen Receptor-dependent Transcriptional Enhancers (*) , 1995, The Journal of Biological Chemistry.

[34]  S. Ohkuma,et al.  Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages , 1981, The Journal of cell biology.

[35]  Aaron Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway , 1994, Cell.

[36]  J. Kleinschmidt,et al.  Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. , 1994, The Journal of biological chemistry.

[37]  M. Parker,et al.  Molecular Determinants of the Estrogen Receptor-Coactivator Interface , 1999, Molecular and Cellular Biology.

[38]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[39]  B. Futcher,et al.  Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis , 2000 .

[40]  T. Willson,et al.  Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. , 2001, Cancer research.

[41]  M. Gilman,et al.  Proteasome‐mediated degradation of transcriptional activators correlates with activation domain potency in vivo , 1999, The EMBO journal.

[42]  D. Fowlkes,et al.  Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β , 1999, Molecular and Cellular Biology.

[43]  B. Katzenellenbogen,et al.  Dynamics of estrogen receptor turnover in uterine cells in vitro and in uteri in vivo. , 1986, Endocrinology.

[44]  B. Katzenellenbogen,et al.  Characterization of the estrogen receptor and its dynamics in MCF-7 human breast cancer cells using a covalently attaching antiestrogen. , 1984, Endocrinology.

[45]  P. Chambon,et al.  Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex , 1990, Cell.

[46]  M. Lippman,et al.  The estrogen receptor in MCF-7 cells: evidence from dense amino acid labeling for rapid turnover and a dimeric model of activated nuclear receptor. , 1984, Endocrinology.